/CABA

Cabaletta Bio Inc

CABA

$2.73USD↓-0.36%-0.01 today

MARKET CAP

462.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$3 – $3

52W RANGE

$2

$4

AI Summary

Stalk

TrimMedium

In a Stage 4 decline with confirmed lower highs and lower lows, the medium-term bias remains bearish. Despite the Bearish Exhaustion pattern suggesting seller fatigue, price has only bounced into declining 9/21 EMA resistance without a decisive rejection. With no clear upside displacement, execution is deferred toward a trim on rallies into the 9 and 21 EMA zone and prior resistance region.

↑Phase 1/2 data show complete B-cell depletion by day 22 in all patients.
↑Management plans to meet FDA in early 2025 on registrational trial design.
↓Q2 2026 net loss of $51M with $44.4M R&D spend underscores cash burn.

Full analysis →

Buying

7

institutions

Selling

5

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
TR T. Rowe Price Investment Management, Inc. Q2 2026	BUY	18.87 M	58.69 M	+7.79 M	+96.9%	0.04%
BI Blackrock, Inc. Q2 2026	BUY	10.75 M	33.45 M	+8.38 M	+424.0%	0.00%
WP Woodline Partners LP Q2 2026	BUY	4.20 M	13.06 M	+1.70 M	+94.2%	0.04%
CA Citadel Advisors LLC Q2 2026	BUY	4.13 M	12.85 M	+3.57 M	+752.0%	0.00%
MM Millennium Management LLC Q2 2026	SELL	2.07 M	6.43 M	+-3.83 M	-59.5%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	1.54 M	4.77 M	+-501.36 K	-12.8%	0.01%
JC Jpmorgan Chase & Co Q2 2026	BUY	59.37 K	184.63 K	+52.16 K	+937.3%	0.00%
AC Adar1 Capital Management, LLC Q2 2026	BUYNEW	50.00 K	155.50 K	+50.00 K	+0.0%	0.01%
RC Rockefeller Capital Management L.P. Q2 2026	BUY	6.75 K	20.99 K	+4.75 K	+290.2%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	SELL	0.00	0.00	+-246.62 K	-100.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-149.72 K	-100.0%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	0.00	0.00	+-11.15 K	-100.0%	0.00%